Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms VHL-targeting PROTAC compound 5 |
Target |
Mechanism BRD2 inhibitors(Bromodomain-containing protein 2 inhibitors), BRD3 inhibitors(Bromodomain-containing protein 3 inhibitors), BRD4 degraders(Bromodomain-containing protein 4 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC47H56ClN9O7S2 |
InChIKeyUAQDCZFGBBSHLT-PBSGCNNPSA-N |
CAS Registry2010159-46-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | GB | 08 Jun 2017 | |
Hematologic Neoplasms | Preclinical | US | 08 Jun 2017 | |
Solid tumor | Preclinical | GB | 08 Jun 2017 | |
Solid tumor | Preclinical | US | 08 Jun 2017 |